A national community-level study of Medicare patients with advanced non-small cell lung cancer found that adding targeted therapy to chemotherapy regimens was not cost-effective.
Prior to vaccines, immunity to a disease was acquired solely through contracting the illness.
There have been multiple concerns levied about PBM tactics that have led plan sponsors and pharmacy stakeholders to push back.
Hot flashes are a huge problem across the general population, but even more so in breast cancer survivors.
With orphan drugs under the microscope, it's important to review the special circumstances and challenges of this group.
Irritable bowel disease, which is defined as chronic idiopathic inflammation of the digestive tract, affects 3.1 million adults in the United States.
Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.
Promoting an environment that allows for rapid problem-solving and execution under high stress is essential to face problems that are poorly understood and yet require rapid change.
Relationship between MS and common herpes virus Epstein-Barr virus offer new treatment target.
Discussion around Michele Bachmann's condition has brought migraine management to the forefront.
A randomized clinical trial offers strong evidence that a combination of 2 targeted melanoma drugs when given continuously keeps cancer from growing or spreading longer compared with intermittent treatment.
This human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate is approved for the treatment of patients with HER2-positive, metastatic breast cancer.
An independent pharmacy in Virginia provides patient care services through an anticoagulation clinic.
This helps ensure that participation increases access to and care of patients of the covered entity.
This paper explores the economic incentives that oncologists face when deciding between oral and intravenous oncolytics and their impact on prescribing behavior.
Examination of pharmacy behaviors before and after implementation indicated that restrictions in pharmacy benefits may not deter utilization for Part D.
Drs. Patel, Singh, and Whalen are postdoctoral fellows in the Rutgers Pharmaceutical Industry Fellowship Program. Dr. Alexander is director of the Institute for Pharmaceutical Industry Fellowships, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey. Dr. Barone is professor and chair of the Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey.
As one of the most visible members of the health care team, pharmacists are uniquely positioned to assist and support patients in tobacco cessation.
In querying pharmacists about what is required to be successful, many so-called “soft skills” in the social and administrative sciences rise to the top, but more evidence is needed.
The past decade has seen a rapid expansion in technology adoption.
Fibromyalgia was related to a pattern of initial increase in utilization and costs, followed by a decrease 7 to 12 months after diagnosis.
Pharmacies with a vision of the future can participate in this thriving market. Small chains and even retailers are establishing a foothold in specialty pharmacy, and they are thriving, while traditional retailers are finding ways to participate actively.
Pharmacists can identify drugs that cause problems, guide selection, and recommend treatment strategies.